BRCA2基因组区域与前列腺癌风险
研究基于英国和爱尔兰1998至2016年招募的447名男性BRCA2致病性变异携带者的前瞻性队列,评估前列腺癌标准化发病比(SIR)及变异位置对风险的影响。结果发现位于PCCR区域的变异携带者PCa的SIR为8.33(95%CI 4.46-15.6),高于其他BRCA2变异携带者的3.31(95%CI 1.97-5.57),风险比(HR)为2.34(95%CI 1.09-5.03);PCCR变异携带者75岁累积PCa风险44%(95%CI 23-72%),85岁为78%(95%CI 54-94%)。研究证实BRCA2中存在前列腺癌聚集区域。
要点
- BRCA2的PCCR区域变异携带者前列腺癌风险显著高于其他区域变异携带者。
- PCCR变异携带者75岁累积前列腺癌风险44%,85岁达78%。
- 建议对BRCA2变异携带者按变异位置进行风险分层管理。
核心结论
- BRCA2致病性变异携带者中,位于PCCR区域的变异与更高的前列腺癌风险相关。
研究设计与样本
- 前瞻性队列研究,纳入1998至2016年英国和爱尔兰招募的447名男性BRCA2致病性变异携带者。
主要发现
- PCCR变异携带者前列腺癌SIR为8.33(95%CI 4.46-15.6),其他BRCA2变异携带者为3.31(95%CI 1.97-5.57)。
- PCCR变异携带者与其他变异携带者相比的风险比(HR)为2.34(95%CI 1.09-5.03)。
- PCCR变异携带者75岁累积前列腺癌风险为44%(95%CI 23-72%),85岁为78%(95%CI 54-94%)。
临床怎么用
- 对BRCA2致病性变异携带者进行前列腺癌风险咨询时,应考虑变异所在基因组区域。
- PCCR区域变异携带者可能需要更密切的前列腺癌筛查和随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A BRCA2 prostate cancer cluster region (PCCR) was recently proposed (c.7914 to 3') wherein pathogenic variants (PVs) are associated with higher prostate cancer (PCa) risk than PVs elsewhere in the BRCA2 gene. Using a prospective cohort study of 447 male BRCA2 PV carriers recruited in the UK and Ireland from 1998 to 2016, we estimated standardised incidence ratios (SIRs) compared with population incidences and assessed variation in risk by PV location. Carriers of PVs in the PCCR had a PCa SIR of 8.33 (95% confidence interval [CI] 4.46-15.6) and were at a higher risk of PCa than carriers of other BRCA2 PVs (SIR = 3.31, 95% CI 1.97-5.57; hazard ratio = 2.34, 95% CI 1.09-5.03). PCCR PV carriers had an estimated cumulative PCa risk of 44% (95% CI 23-72%) by the age of 75 yr and 78% (95% CI 54-94%) by the age of 85 yr. Our results corroborate the existence of a PCCR in BRCA2 in a prospective cohort. PATIENT SUMMARY: In this report, we investigated whether the risk of prostate cancer for men with a harmful mutation in the BRCA2 gene differs based on where in the gene the mutation is located. We found that men with mutations in one region of BRCA2 had a higher risk of prostate cancer than men with mutations elsewhere in the gene.
引用
- Nyberg T, Frost D, Barrowdale D, et al. Prostate Cancer Risk by BRCA2 Genomic Regions. Eur Urol. 2020. PMID: 32532514. doi:10.1016/j.eururo.2020.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。